Tagrisso®

Active substance

Osimertinib

Holder

AstraZeneca SA/NV

Status

Closed

Indication

Tagrisso® is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).

Public documents

Approbation

Information for the patient

Informed consent

Last update

01/12/2016

Last updated on 17/11/2022